Company Overview

Mesa Laboratories, Inc. is a U.S.-based life sciences company that develops, manufactures, and sells quality control (QC) instruments, devices, and consumables used in regulated environments. The company operates primarily within the healthcare, pharmaceutical, medical device, and biotechnology industries, supporting customers that require validated measurement, calibration, and compliance assurance for critical manufacturing and clinical processes.

Mesa’s primary revenue drivers are its four operating segments: Biopharmaceutical Development, Calibration Solutions, Clinical Genomics, and Sterilization and Disinfection Control. These segments serve pharmaceutical manufacturers, medical device companies, clinical laboratories, hospitals, and research institutions. The company is positioned as a specialized provider of compliance-critical products with recurring revenue characteristics driven by consumables, service contracts, and long product lifecycles. Founded in 1982, Mesa initially focused on calibration instruments and has evolved through organic development and acquisitions into a diversified life sciences QC platform.

Business Operations

Mesa operates through four reportable segments. Biopharmaceutical Development provides automated systems, instruments, and consumables used in protein analysis, stability testing, and formulation development, generating revenue through instrument sales and recurring consumables. Calibration Solutions offers precision measurement devices, sensors, and calibration services used to verify critical parameters such as temperature, pressure, and flow in regulated environments.

The Clinical Genomics segment supplies genomic analysis tools, including sample preparation and DNA quality assessment products, primarily for research and clinical laboratory customers. Sterilization and Disinfection Control delivers biological and chemical indicators, monitoring systems, and related services that verify sterilization processes in pharmaceutical, medical device, and healthcare settings. Mesa conducts operations in both domestic and international markets and controls proprietary technologies, manufacturing facilities, and specialized testing capabilities through its wholly owned subsidiaries.

Strategic Position & Investments

Mesa’s strategic direction emphasizes expanding its recurring revenue base, increasing exposure to biopharmaceutical and clinical markets, and leveraging acquisitions to deepen technical capabilities. Growth initiatives focus on cross-selling across segments, continued investment in regulated consumables, and innovation in automation and data-driven QC solutions. The company has historically pursued disciplined acquisitions to enter adjacent life sciences niches and strengthen its portfolio.

Notable acquired businesses integrated into Mesa’s platform include Gyros Protein Technologies, Agena Bioscience, and GKE, which expanded the company’s presence in biopharmaceutical analytics, clinical genomics, and sterilization assurance, respectively. Mesa continues to invest in emerging analytical technologies and compliance-driven tools that align with increasingly stringent regulatory standards in healthcare and life sciences manufacturing.

Geographic Footprint

Mesa Laboratories is headquartered in the United States, with its principal executive offices in Colorado. The company maintains a significant operational presence across North America, Europe, and Asia-Pacific, serving customers in more than 50 countries through direct sales organizations and distribution partners.

International operations include manufacturing, sales, and service facilities in key life sciences markets such as Western Europe, the United Kingdom, and parts of Asia, supporting global pharmaceutical, medical device, and clinical laboratory customers. This geographic diversification allows Mesa to participate in global regulatory-driven demand while mitigating reliance on any single regional market.

Leadership & Governance

Mesa Laboratories is led by an executive team with extensive experience in life sciences instrumentation, regulated manufacturing, and operational integration. The company’s leadership emphasizes disciplined capital allocation, regulatory compliance, and long-term value creation through recurring revenue models and technical differentiation.

Key executives include:

• Gary L. Owens – President and Chief Executive Officer
• Eric L. Krum – Chief Financial Officer
• John J. Sullivan – Executive Vice President and President, Sterilization and Disinfection Control
• Scott Glenn – Executive Vice President and President, Biopharmaceutical Development
• Garry R. Ridgway – Executive Vice President and President, Calibration Solutions

The company operates under a governance framework aligned with U.S. public company standards, with oversight by an independent board of directors and compliance with applicable regulatory and reporting requirements under SEC filings.